We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Polyplus Launches FectoVIR®-LV Transfection Reagent with New DOE Service Options

Cell culture in a 12 well plate.
Credit: iStock.
Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: 1 minute

Polyplus (now part of Satorius), is announcing the pre-order availability of FectoVIR®-LV transfection reagent for lentiviral vector (LV) production. New design of experiment (DoE) services can also be booked complimentary with Polyplus experts to optimize transfection conditions for improved LV vector titers and quality in suspension systems.


“LV vector production is currently considered the carrier of choice for gene-modified cell therapy such as CAR-T and stem cell therapies. But as advancements continue in both the autologous and allogeneic cell therapy sectors, the quantity of LV required to treat a patient will grow. Producers must be able to scale their processes to increase the dose, while still paying close attention to the time and cost of manufacturing,” said Mario Philips, CEO at Polyplus. “Along with the introduction of design of experiment (DoE) services we can help innovators and contract manufacturers teams review process parameters and run experiments to optimize transfection.”

Want more breaking news?

Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.

Subscribe for FREE

FectoVIR®-LV is a next generation transfection reagent that helps to improve LV productivity in suspension HEK-293 cell systems. The reagent is free of animal components and designed for large scale manufacturing with reduction of the complexation volume and increased complex stability.


“Manufacturers see much better results working with reagents that are both specific to the process, and easily scalable to meet process demands,” said Patrick Erbacher, CSO “Our team has long been an innovator in nucleic acid delivery with a comprehensive range of process-centric reagents. The addition of FectoVIR®-LV allows manufacturers of these innovative therapies to increase the number of doses produced per batch to treat more patients, while decreasing manufacturing costs. Our owned and secured supply chain is an additional benefit ensuring that processes are not interrupted.”